Clinical aspects of myasthenia explained.
Myasthenia gravis and myasthenic syndromes are diseases of the neuromuscular junction. Autoantibodies and toxins to or mutations in one of the synaptic proteins are the main causes of dysfunction. Myasthenic phenotypes can be classified according to the basic aetiological mechanisms or divided depending on the clinical phenotype.
Verschuuren
Jan J G M
JJ
Department of Neurology, Leiden University Medical Center (LUMC), Leiden, The Netherlands. j.j.g.m.verschuuren@lumc.nl
Palace
Jackie
J
Gilhus
Nils Erik
NE
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D015624:Lambert-Eaton Myasthenic Syndrome / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000503:physiopathology; D009132:Muscles / Q000503:physiopathology; D009154:Mutation; D009157:Myasthenia Gravis / Q000453:epidemiology / Q000276:immunology* / Q000503:physiopathology*; D020294:Myasthenic Syndromes, Congenital / Q000276:immunology / Q000503:physiopathology; D009469:Neuromuscular Junction / Q000276:immunology / Q000503:physiopathology*; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D011950:Receptors, Cholinergic / Q000235:genetics / Q000276:immunology; D009435:Synaptic Transmission
D001323:Autoantibodies; D011950:Receptors, Cholinergic; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases